Meeting
2022 ASCO Annual Meeting
Prior authorizations for PARP inhibitors in ovarian cancer.
Authors
Audra Hugo
University of Pennsylvania, Philadelphia, PA
Audra Hugo , Daniella Pena , Emily Meichun Ko , Ashley Ford Haggerty , Anna Jo Bodurtha Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5549)
DOI
10.1200/JCO.2022.40.16_suppl.5549
Abstract #
5549
Poster Bd #
428
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.
First Author: Mansoor Raza Mirza
Poster
2021 ASCO Annual Meeting
Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
First Author: Stephanie L. Wethington
Poster
2019 ASCO Annual Meeting
Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.
First Author: Mansoor Raza Mirza
Poster
2017 ASCO Annual Meeting
Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).
First Author: Ursula A. Matulonis